Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)    
$91.83 4.62 (5.3%) as of 4:30 Thu 12/18


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 148,000,000 as of 9/30
Market Cap: 13.59(B)
Last Volume: 1,422,601 Avg Vol: 1,240,469
52 Week Range: $56.17 - $92.9
Level I Sector: Health Care
Level II Sector:   Drugs
Level III Sector:      Drug Manufacturers - Other

Member Indexes:

    NASDAQ BIOTECHNOLOGY       NASDAQ COMPOSITE  
    NASDAQ NNM COMPOSITE  

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
 

Company Profile   BioMarin Pharmaceutical develops and commercializes pharmaceuticals. Co.'s approved products include: Naglazyme (galsulfase) for patients with mucopolysaccharidosis VI; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Aldurazyme (laronidase) for patients with mucopolysaccharidosis I; and Firdapse (amifampridine phosphate) for the treatment of Lambert Eaton Myasthenic Syndrome. Co. is also conducting clinical trials on several investigational product candidates including, among others: Vimizim™, for the treatment of mucopolysaccharidosis Type IV or Morquio Syndrome Type A; and PEG-PAL for the treatment of phenylketonuria.

 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 181,322 234,316 345,485 1,098,827
Total Sell Value $15,433,499 $19,054,257 $27,077,274 $74,508,265
Total People Sold 7 8 9 13
Total Sell Transactions 18 24 48 134
End Date 2014-09-21 2014-06-20 2013-12-20 2012-12-20

   
Records found: 1290
  Page 1 of 52  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-12-10 4 OE $12.99 $25,980 I/I 2,000 45,195     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-12-10 4 AS $95.00 $190,000 I/I (2,000) 43,195 0%     
   Lewis Alan Director   –       •      –    2014-12-04 4 OE $21.51 $161,325 D/D 7,500 28,900     -
   Lewis Alan Director   –       •      –    2014-12-04 4 S $89.90 $674,225 D/D (7,500) 21,400 -2%     
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-12-03 4 OE $38.59 $463,080 D/D 12,000 43,590     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-12-03 4 S $91.01 $1,092,161 D/D (12,000) 31,590 -1%     
   Mueller Brian VP, Corporate Controller   •       –      –    2014-12-02 4 OE $28.23 $141,150 D/D 5,000 9,593     -
   Mueller Brian VP, Corporate Controller   •       –      –    2014-12-02 4 S $91.82 $459,100 D/D (5,000) 4,593 -1%     
   Mueller Brian VP, Corporate Controller   •       –      –    2014-12-01 4 OE $14.39 $145,785 D/D 6,950 11,543     -
   Mueller Brian VP, Corporate Controller   •       –      –    2014-12-01 4 S $90.25 $627,238 D/D (6,950) 4,593 -2%     
   Mueller Brian VP, Corporate Controller   •       –      –    2014-11-26 4 S $88.97 $302,508 D/D (3,400) 4,593 -3%     
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-11-25 4 OE $12.99 $25,980 I/I 2,000 45,195     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-11-25 4 AS $90.00 $180,000 I/I (2,000) 43,195 3%     
   Davis George Eric SVP, General Counsel   •       –      –    2014-11-25 4 OE $26.49 $529,800 D/D 20,000 84,426     -
   Davis George Eric SVP, General Counsel   •       –      –    2014-11-25 4 AS $89.75 $1,795,000 D/D (20,000) 64,426 3%     
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-11-12 4 S $81.51 $81,513 D/D (1,000) 228,157 -6%     
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-11-10 4 OE $12.99 $51,960 I/I 4,000 47,195     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-11-10 4 S $87.00 $348,000 I/I (4,000) 43,195 -5%     
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-11-10 4 OE $21.51 $430,200 D/D 20,000 96,550     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-11-10 4 S $86.55 $1,730,982 D/D (20,000) 76,550 -5%     
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-11-03 4 AS $83.54 $3,926 D/D (47) 31,590 11%     
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-11-03 4 S $85.33 $256,002 I/I (3,000) 43,195 -11%     
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2014-10-31 4 A $31.26 $1,469 D/D 47 31,637     -
   Baffi Robert EVP, Technical Operations   •       –      –    2014-10-30 4 OE $38.59 $1,156,272 D/D 29,963 129,163     -
   Baffi Robert EVP, Technical Operations   •       –      –    2014-10-30 4 S $81.70 $2,447,959 D/D (29,963) 99,200 -14%     

  1290 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 52
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed